On November 24, Lilly Pharmaceutical and Boehringer Ingelheim jointly announced that Outangjing& Reg; The new indication of Engliflozin has been approved by the National Drug Administration of China for the treatment of adult chronic kidney disease (CKD).
This is after adult type 2 diabetes, adult heart failure with reduced ejection fraction, adult heart failure with preserved ejection fraction, and combined insulin treatment of type 2 diabetes; Reg; Another new indication approved in China. In addition to the existing indications for type 2 diabetes and heart failure, Ou Tangjing& Reg; Helps manage risks caused by cardiovascular metabolic diseases. Since its listing, it has benefited over 1 billion patients worldwide.
Liu Zhihong, an academician of the CAE Member and director of the National Clinical Medical Research Center for Renal Diseases, said that chronic kidney disease is a major disease threatening public health around the world. In China, because of the improvement of public education, medical services and environmental protection in the past decade, the prevalence of CKD among adults over 18 years old has dropped from 10.8% to 8.2%. But because of the high incidence rate of CKD, the high rate of combined cardiovascular disease, and the high rate of death and disability; The "three highs and three lows" characteristics of low awareness rate, low consultation rate, and low control rate still impose a considerable burden on patients, their families, and even society. This approval has enabled Ou Tangjing to; Reg; Bringing safe and effective new treatment options to Chinese patients is expected to improve the treatment prospects of more CKD patients.